A fresh $25.0M Series A funding round is set to accelerate Altis Labs' mission to streamline clinical trials, a critical bottleneck in bringing new therapies to market. The company applies artificial intelligence to reduce the time, cost, and failure rate plaguing therapeutic development, aiming to get novel treatments to patients sooner.
At the core of its offering is IPRO, an AI model trained on the industry's largest multimodal oncology database linked to survival outcomes. IPRO generates survival predictions from radiology scans, enabling leading global biopharmaceutical companies and cancer research centers to detect efficacy signals earlier and make development decisions with greater confidence.
